[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371309-105":59,"doc-detail-371309-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","characterization-of-alternative-spd-1-isoforms-reveals-that-ecd-spd-1-signature-predicts-an-efcient-antitumor-response","Characterization of alternative sPD-1 isoforms reveals that ECD sPD-1 signature predicts an efﬁcient antitumor response","","Soluble PD-1 (sPD-1) is a dissociated form of membrane PD-1 found in cancer, infections, and autoimmune diseases, but its clinical significance remains unclear due to uncertainty about its isoforms, origin, and production mechanism. Using antibodies binding to PD-1 intracellular domains, two sPD-1 isoforms were identified at the protein level: FL sPD-1 and ECD sPD-1. In tumor models, activated CD8 T cells generated both isoforms; however, ECD sPD-1 was released by matrix metalloproteinases, while FL sPD-1 production accompanied PD-1+ T cell death. ECD sPD-1 uniquely predicted effective immune response and better tumor outcomes, positioning it as a prognostic biomarker. A meta-analysis and ELISA-based isoform assays further supported these findings.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/characterization-of-alternative-spd-1-isoforms-reveals-that-ecd-spd-1-signature-predicts-an-efcient-antitumor-response/371309/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/characterization-of-alternative-spd-1-isoforms-reveals-that-ecd-spd-1-signature-predicts-an-efcient-antitumor-response/371309.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What two soluble PD-1 (sPD-1) isoforms were identified, and how do they differ?","Question",{"text":112,"@type":113},"The study identified two sPD-1 isoforms at the protein level: FL sPD-1 containing both extra- and intracellular domains, and ECD sPD-1 containing only the extracellular fragment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Where do the sPD-1 isoforms originate in tumor models?",{"text":117,"@type":113},"In tumor models, both sPD-1 isoforms were generated by activated CD8 T cells that highly express membrane PD-1.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is ECD sPD-1 considered more predictive than other sPD-1 forms?",{"text":121,"@type":113},"ECD sPD-1 was released from live PD-1+ T cells via matrix metalloproteinases, while FL sPD-1 production occurred alongside PD-1+ T cell death; only ECD sPD-1 predicted effective immune response and better tumor outcome, supporting its prognostic value.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},371309,1790609532,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","communications biology Article  \n\n| A Nature Portfolio journal |  | |\n| --- | --- | --- |\n| [https://doi.org/10.1038/s42003-025-07800-x](https://doi.org/10.1038/s42003-025-07800-x) |  |  |\n| Characterization of alternative sPD-1 isoforms reveals that ECD sPD-1 signature predicts an efﬁcient antitumor response\u003Cbr> Check for updates |  |  |\n| Ping Hou1,4, Li Hu1,4, Junrong Zhang2, Xiaoyan Zhou3, Yonglei Xiao1, Lijun Li1, Qiongwen Wu1, Jing Liu1, Yuhong Lin 3  & Ling Chen 1  |  |  |\n| Soluble PD-1 is a dissociated form of membrane PD-1 broadly present in cancer, infections, or autoimmune diseases. However, the clinical signiﬁcance of sPD-1 remains controversial due to the uncertainty of its isoforms, origin, and production mechanism. Here, using antibodies speciﬁcally binding to the intracellular domain of PD-1, we identiﬁed two sPD-1 isoforms in cancers at the protein level: FL sPD-1 containing both the extra-and intracellular domains of PD-1, and ECD sPD-1 containing only the extracellular fragment. Subsequently, we tracked their origin and found that in tumor models, both sPD-1 isoforms were generated by activated CD8 T cells highly expressing membrane PD-1 . However, ECD sPD-1 was released from live PD-1+T cells by matrix metalloproteinases, while FL sPD-1 production was accompanied by PD-1+T cell death. Therefore, only ECD sPD-1 predicts effective immune response and better tumor outcome. Our study distinguished sPD-1 isoforms and highlighted ECD sPD-1 as a prognostic biomarker in cancer. |  |  |\n| Programmed death-1 (PD-1) is a crucial inhibitor of an immune response. Full-length (FL) PD-1 is a typical type I transmembrane protein consisting of an extracellular domain (ECD), a transmembrane region (TM), and an intracellular domain (ICD)1. A soluble form of PD-1 (soluble PD-1, sPD-1) has been reported in diseases, including cancers2,3, inﬂammation4,5, and autoimmune disorders6,7. Given the promising application of anti-PD-1 therapy in malignant tumors, the clinical signiﬁcance ofsPD-1in cancer has been explored. Some studies showed that high levels of sPD-1 in cancers were associated with aggressive tumor growth and advanced stages8–10while others observed the opposite or no correlation11, 12. Likewise, when tumors were treated with targeted therapies or immunotherapies, the correlation between sPD-1 increase and therapeutic response was not conclusive13–17. Further elucidation of sPD-1 isoforms, origin, and production mechanism would help to clarify these questions.\u003Cbr>In contrast to extensive clinical association studies, there are fewer reports on the isoforms and production mechanisms of sPD-1. Although ﬁve alternatively spliced PD-1 mRNA transcripts were observed in naïve peripheral blood mononuclear cells (PBMCs)18, these variants were not conﬁrmed at the protein level. Furthermore, most sPD-1 examinations | utilized antibodies that bind to the ECD fragment of PD-114–16; however, no soluble ECD PD-1transcript wasidentiﬁed, suggesting that mRNA splicing may not be the only mechanism for sPD-1 production. In contrast, some studies have reported that the amount of sPD-1 was positively correlated with the level of membrane PD-1 (mPD-1) on T cells5, 17, 19, implying that sPD-1 may be directly derived from expressed PD-1. PD-1 is expressed on multiple cells, including T, B, and NK cells20–24. On T cells, PD-1 can be upregulated upon antigen priming1,25,26, and to avoid overactivation, it generally decreaseswhen the immune response is completed. Persistent PD- 1 expression results in T-cell exhaustion and dysfunction, leading to immune abnormalities and disease27. Recent studies have shown that the downregulation ofPD-1also occurs atthe protein level28,29, which may result in sPD-1 production; however, further investigation is warranted to address this.\u003Cbr>Herein, we started withameta-analysis ofsPD-1in cancers. Then, two enzyme-linked immunosorbent assay (ELISA) systems were developed to distinguish different isoforms ofsPD-","cbCaif7MUHUOz7OK","https://ap.wps.com/l/cbCaif7MUHUOz7OK","pdf",1165332,12,"English","# Background\n## Soluble PD-1 controversies and clinical associations\n## Need for clarification of isoforms, origin, and production\n# Study design\n## Meta-analysis of sPD-1 and cancer prognosis\n## ELISA systems for isoform distinction\n## Cellular origin and production explored in murine models\n# Results\n## Meta-analysis outcomes for baseline sPD-1 and survival\n## Heterogeneity and qualitative meta-analysis","[{\"question\":\"What two soluble PD-1 (sPD-1) isoforms were identified, and how do they differ?\",\"answer\":\"The study identified two sPD-1 isoforms at the protein level: FL sPD-1 containing both extra- and intracellular domains, and ECD sPD-1 containing only the extracellular fragment.\"},{\"question\":\"Where do the sPD-1 isoforms originate in tumor models?\",\"answer\":\"In tumor models, both sPD-1 isoforms were generated by activated CD8 T cells that highly express membrane PD-1.\"},{\"question\":\"Why is ECD sPD-1 considered more predictive than other sPD-1 forms?\",\"answer\":\"ECD sPD-1 was released from live PD-1+ T cells via matrix metalloproteinases, while FL sPD-1 production occurred alongside PD-1+ T cell death; only ECD sPD-1 predicted effective immune response and better tumor outcome, supporting its prognostic value.\"}]","Characterization of alternative sPD-1 isoforms reveals that ECD sPD-1 signature predicts an efﬁcient antitumor response | PDF",1790191768,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ceccc9311340d7229948a5c26b9c96d.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2eeb3783036afdcb2be5fa2869b272b2.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2750167bda5c5ef5cf1d81926c8aabe5.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b64a095e387e8784a5f3198db9b6197.webp",980,1301]